Daiichi Sankyo Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Ebitda" stands at 385.49 Billion Japanese Yens for the trailing twelve months (TTM) period ending 06/30/2025, the highest value at least since 12/31/2011, the period currently displayed.
Daiichi Sankyo Co. Ltd.'s first quarter result of 114.51 Billion JPY for the item "Ebitda" represents an increase of 40.35 percent compared to it's fourth quarter result of the company's last fiscal year.
Also, Daiichi Sankyo Co. Ltd.'s first quarter result of 114.51 Billion JPY for the item "Ebitda" represents an increase of 4.49 percent compared to it's first quarter result of last year.
Looking again at the trailing twelve months series (TTM), Daiichi Sankyo Co. Ltd.'s first quarter result of 385.49 Billion JPY for the item "Ebitda" represents an increase of 1.29 percent compared to it's fourth quarter result of the company's last fiscal year.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 19.52 percent compared to the value the year prior.
The 1 year change in percent is 19.52.
The 3 year change in percent is 221.06.
The 5 year change in percent is 127.13.
The 10 year change in percent is 166.99.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Ebitda | 905,699,262,464.00 |
![]() | Johnson & Johnson - Ebitda | 486,508,953,600.00 |
![]() | AbbVie Inc - Ebitda | 399,570,305,024.00 |
![]() | Roche Holding AG - Ebitda | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Ebitda | 280,205,508,085.11 |